Zelnorm (Zelmac) IBS Medication

The Benefits of Zelnorm (Zelmac) IBS Medication.

The mission statement of Novartis pharmaceuticals is: We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. As the developer of Zelnorm (Zelmac) Novartis pharmaceuticals makes and sells Zelnorm (Zelmac) irritable bowel syndrome (IBS)medication, which won approval from the FDA in 2002. In March of 2007, the FDA asked Novartis to pull the drug because several studies seemed to point to cardiovascular risk in individuals who had been identified as having cardiovascular issues. The drug may still be prescribed on a limited basis, and the drug is / was particularly effective for certain individuals, and for some was the most promising treatment available. According to mayoclinic. Com, IBS is one of the most common disorders with 1 in 5 Americans experiencing the following symptoms: Abdominal Cramping Bloating and Gas Diarrhea, constipation or both Although some individuals can control IBS by controlling their diet, lifestyle, or stress level, some individuals will experience a marked improvement once prescribed Zelnorm (Zelmac) IBS medication. IBS is controlled one of several ways: low-dose antidepressants to control abdominal nerve endings antispasmodics to control intestinal muscle spasm and abdominal pain musculotropic antispasmodics to relieve spasms in the smooth muscle cells and intestines medications that slow down the speed of food moving through the digestive system laxatives. According to Drugs.

Com, "Zelnorm (Zelmac) IBS medication increases the action of a chemical called serotonin in the intestines. This speeds the movement of stools through the bowels. Zelnorm is used to treat severe, chronic, irritable bowel syndrome in women who have constipation (and not diarrhea) as their main bowel problem. It is also used to treat chronic constipation in patients younger than 55 years old. " MayoClinic. Com also lists the following medications for treatment of IBS in women: Alosetron (Lotronex) which is a nerve receptor antagonist slows the movement of waste through the lower bowel. Alosetron was removed from the market just nine months after its approval when it was linked to at least two deaths and severe side effects in 113 people.

In June 2002, the Food and Drug Administration (FDA) allowed alosetron to be sold again — with restrictions. Lubiprostone (Amitiza). The FDA approved Amitiza in April 2008 to treat women age 18 and older who have IBS with constipation. Amitiza works by increasing fluid secretion in the small intestine to help with the passage of stool. Common side effects include nausea, diarrhea and abdominal pain. The benefits of Zelnorm (Zelmac) IBS medication are clear and should be discussed with your physician as an effective option with fewer side effects in its' control of IBS.